ADC Therapeutics SA secures $86.6 million in Private Equity financing, with participation from Bain Capital Life Sciences and existing investors. This strategic move aims to extend the company's cash runway into 2029.
Amount Raised
$86.6 Million
Round Type
Post-IPO Equity
LausanneBiotechnologyHealth CareTherapeuticsInvestors
Description
ADC Therapeutics SA has announced a strategic financial restructuring, which includes a $86.6 million private placement involving both new and existing investors. This financing effort is intended to enhance the company’s capital structure and extend its cash runway. The deal includes participation from Bain Capital Life Sciences among others. The restructuring aims to maximize shareholder value and reduce leverage.
Quick answer
ADC Therapeutics raised $86.6 Million in a Post-IPO Equity round, dated October 7, 2026. Investors: Nantahala Capital, Tcgx, Redmile and Bain Capital Life Sciences. ADC Therapeutics is based in Lausanne, Vaud, Switzerland.
- How much did ADC Therapeutics raise?
- ADC Therapeutics raised $86.6 Million in a Post-IPO Equity round on October 7, 2026.
- Who invested in ADC Therapeutics?
- Nantahala Capital, Tcgx, Redmile and Bain Capital Life Sciences are named as investors in this round.
- What does ADC Therapeutics do?
- ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs).
- Where is ADC Therapeutics based and how big is it?
- ADC Therapeutics is based in Lausanne, Vaud, Switzerland. Fundz records about 318 employees.
- Who are the decision-makers at ADC Therapeutics?
- Fundz holds 1 contact at ADC Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as ADC Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- VectorY raised $83M on November 11, 2026.
- Neurosterix raised $105M (Series B) on November 11, 2026.
- Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
- SRTD biotech raised $35M (Seed) on November 9, 2026.
Who to call at ADC Therapeutics, and when
A new round usually means ADC Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day ADC Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at ADC Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at ADC Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment ADC Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
ADC Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.